Health Catalyst, Inc. (NASDAQ:HCAT) Receives Average Recommendation of “Hold” from Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has earned an average recommendation of “Hold” from the thirteen analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $2.7955.

A number of research firms recently commented on HCAT. Stephens decreased their price objective on Health Catalyst from $3.50 to $2.00 and set an “equal weight” rating on the stock in a research note on Friday, March 13th. Cantor Fitzgerald reduced their target price on Health Catalyst from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Friday, March 13th. Wells Fargo & Company reiterated an “equal weight” rating and set a $1.00 target price (down from $5.00) on shares of Health Catalyst in a research report on Wednesday, March 18th. Citigroup reduced their target price on Health Catalyst from $2.75 to $1.75 and set a “neutral” rating on the stock in a research report on Friday, March 13th. Finally, Stifel Nicolaus reduced their target price on Health Catalyst from $3.75 to $2.00 and set a “hold” rating on the stock in a research report on Friday, March 13th.

Health Catalyst Stock Down 6.4%

HCAT opened at $1.03 on Thursday. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 0.62. The firm has a market cap of $75.80 million, a P/E ratio of -0.41 and a beta of 1.81. Health Catalyst has a 52 week low of $1.02 and a 52 week high of $5.06. The business’s fifty day simple moving average is $1.63 and its 200 day simple moving average is $2.30.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The company had revenue of $74.68 million for the quarter, compared to analyst estimates of $73.99 million. Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 4.30%. As a group, equities research analysts anticipate that Health Catalyst will post -0.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

Several large investors have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new position in shares of Health Catalyst in the 4th quarter worth about $25,000. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Health Catalyst in the 3rd quarter worth about $39,000. Cresset Asset Management LLC purchased a new position in shares of Health Catalyst in the 2nd quarter worth about $39,000. FNY Investment Advisers LLC purchased a new position in shares of Health Catalyst in the 3rd quarter worth about $45,000. Finally, Focus Partners Wealth purchased a new position in shares of Health Catalyst in the 1st quarter worth about $46,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.